Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Bows Out Of Partnership With AstraZeneca On Phase III Brodalumab

This article was originally published in The Pink Sheet Daily

Executive Summary

Company drops deal to co-develop and commercialize the IL-17 blocker in psoriasis, cites reports of suicidal ideation.

You may also be interested in...

Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry

Agency's advisors were divided on whether Valeant's proposal for voluntary registry would suffice or whether mandatory program under REMS was needed to better assess risk of suicide and suicidal behavior with psoriasis drug.

Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk

Advisory committee will hear agency reviewers' different conclusions on plaque psoriasis drug's approvability due to potential psychiatric effects and whether a REMS can help mitigate the risks.

Amgen Gets Cost-Sharing, MedImmune A Pipeline Boost In Five-Antibody Collaboration

Amgen and the AstraZeneca biologics subsidiary will co-develop and commercialize five monoclonal antibodies in inflammation and respiratory indications, led by brodalumab, which recently posted impressive Phase II data in psoriasis.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts